- Reaction score
- 1,336
Maybe the way they inject and the frequency. 3 treatments in 6 months and 2ml of serum in temples and crown. The drawing is showing a nw5 or 6. Does it matter?
Histogen investor update:
https://investors.histogen.com/static-files/5142405a-875a-4984-a672-2b5765fa2785
My question would be when is it out to market if passes phase 3? I’m guessing out in Mexico first?
It will be out on those markets that acknowledges FDA clinical trails and processes. And then the company that gets approved needs to be able to ramp out the production, do marketing and so on, and then have a product launch.
But first they need to get get approved and about 90% fails to get complete all clinical trails and get FDA approved. So still a very long way, we are still talking years.
My question would be when is it out to market if passes phase 3? I’m guessing out in Mexico first?
Thanks for the update.Histogen had a deal with a company a while back to bring it to market in Mexico but the partner skipped out on Histogen. Histogen has since then reformulated HSC so it no longer contains animal products like bovine albumin and made it so it only contains human products. Its basically a complete restart so they are in phase 1b/2a trials right now partnering with a company in China called Huapont.
SAN DIEGO, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), today announced preliminary week 18 results from its Phase 1b/2a clinical trial of HST-001 in male patients with androgenic alopecia. At the week 18 primary efficacy endpoint, patients treated with HST-001 demonstrated separation from placebo patients for absolute change from baseline in total hairs (terminal and vellus) in the target area (TAHC) in the vertex as measured by Canfield’s Hairmetrix macrophotography system. HST-001 was also shown to be safe and well tolerated at week 18 as compared to placebo with no reports of serious adverse events.
“While HST-001 did not achieve statistical significance at the week 18 primary endpoint assessment, we are encouraged that these results demonstrated separation from placebo and that patients treated with HST-001 grew new hairs in the vertex region of the scalp while placebo patients lost hairs in the same region during the 18 week evaluation period,” said Richard W. Pascoe, Histogen’s President and CEO. “We look forward to completing the study and reporting the final results from the week 26 assessments, along with our plans for further clinical development of HST-001, in early first quarter of 2021.”
I had high hopes for this...
thier phase 1b/2a results:
Fkcing histogen man a company that disappoints time and time again.
Oh well, maybe it's good enough for maintenance...
I never understood this though. I think these companies VASTLY underestimate how big the market is for a safe maintenance treatment.
Histogen Announces Preliminary Week 18 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men
Histogen Announces Preliminary Week 18 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men
HST-001 Demonstrated Separation from Placebo at Week 18 Primary Efficacy Endpoint Assessment HST-001 Found to be Safe and Well Tolerated with No Serious...www.globenewswire.com
Dont know if this had been posted yet.
Not awesome but Still I’m looking forward to 26 week resultsI had high hopes for this...
thier phase 1b/2a results:
Propecia is very popular. Half billion in revenues, and over ten million Americans take finasteride. Most people don't care about the side effects, only the autists on the message boards.
I'd apply for Mexican citizenship if it would only work.What a joke...
How come they pushed HST001 till phase 3 in Mexico a while ago, to now discover it's not actually doing anything... hahaha
It must only be efficient to the Mexican scalp.
The one and only thing both jan_miezda and jan miedza agree onhistogen is sh*t